“Genome-Wide Association Study and Multi-Trait Analysis of Opioid Use Disorder Identifies Novel Associations in 639,709 Individuals of European and African Ancestry”, 2021-12-15 (; similar):
Background: Despite the large toll of opioid use disorder (OUD), genome-wide association studies (GWAS) of OUD to date have yielded few susceptibility loci.
Method: We performed a large-scale GWAS of OUD in individuals of European (EUR) and African (AFR) ancestry, optimizing genetic informativeness by performing MTAG (Multi-trait analysis of GWAS) with genetically correlated substance use disorders (SUDs). Meta-analysis included 7 cohorts: the Million Veteran Program (MVP), Psychiatric Genomics Consortium (PGC), iPSYCH, FinnGen, Partners Biobank, BioVU, and Yale-Penn 3, resulting in a total n = 639,709 (Ncases = 20,858) across ancestries. OUD cases were defined as having lifetime OUD diagnosis, and controls as anyone not known to meet OUD criteria. We estimated SNP-heritability (h2SNP) and genetic correlations (rg). Based on genetic correlation, we performed MTAG on OUD, alcohol use disorder (AUD), and cannabis use disorder (CanUD).
Results: The EUR meta-analysis identified 3 genome-wide statistically-significant (GWS; p≤5×10−8) lead SNPs—one at FURIN (rs11372849; p = 9.54×10−10) and two OPRM1 variants (rs1799971, p = 4.92×10−09; rs79704991, p = 1.37×10−08; r < sup>2=0.02). Rs1799971 (p = 4.91×10−08) and another OPRM1 variant (rs9478500; p = 1.95×10−8; r < sup>2=0.03) were identified in the cross-ancestry meta-analysis. Estimated h2SNP was 12.75%, with strong rg with CanUD (rg =0.82; p = 1.14×10−47) and AUD (rg = 0.77; p = 6.36×10−78). The OUD-MTAG resulted in 18 GWS loci, some of which map to genes or gene regions that have previously been associated with psychiatric or addiction phenotypes.
Conclusion: We identified multiple OUD variant associations at OPRM1, single variant associations with FURIN, and 18 GWS associations in the OUD-MTAG. OUD is likely influenced by both OUD-specific loci and loci shared across SUDs.